Less than 1% of heart failure (HF) patients with reduced ejection fraction are on target doses of all four drug classes within 12 months of an index hospitalization, yet these protocols have been proven to improve symptoms, slow disease progression, reduce costly admissions, and increase life expectancy. This data point must serve as a rallying cry in the nation’s quest to combat heart failure as a leading cause of death.
We take pride in providing you with relevant, useful content. May we use cookies to track what you read? We take your privacy very seriously. Please see our privacy policy for details and any questions.